Triple-Negative Breast Cancer (TNBC): Symptoms, Stages, Diagnosis & Treatment

Triple-negative breast cancer (TNBC) is breast cancer that does not have significant expression of estrogen receptors (ER), progesterone receptors (PR), or HER2. Because these three markers are “negative,” treatments that specifically target them — hormone therapy for ER/PR-positive cancers, and HER2-targeted drugs for HER2-positive cancers — generally don’t work the same way for TNBC.

A few things worth being clear about immediately:

• TNBC is a subtype of breast cancer, defined by this specific biomarker profile — not a completely separate disease
• “Triple-negative” describes the tumor’s receptor status, not a general statement about three negative test results in some broader sense
• TNBC accounts for roughly 10–20% of breast cancers, and disproportionately affects younger women
• TNBC is not untreatable — chemotherapy has long been central to its treatment, and in recent years immunotherapy, PARP inhibitors, and targeted antibody-drug conjugates have meaningfully expanded what’s available, depending on stage and additional biomarkers
• TNBC is genuinely biologically diverse — not every TNBC tumor behaves the same way, which is exactly why treatment increasingly depends on more than the TNBC label alone

What Does “Triple-Negative” Actually Mean?

“Triple-negative” refers to three specific biomarkers tested on every breast cancer biopsy: estrogen receptor (ER), progesterone receptor (PR), and HER2. When all three come back negative, the cancer is classified as TNBC.

Exact testing thresholds and interpretation follow current pathology guidelines and can involve some nuance (discussed further in the HER2-low section below) — this isn’t always a simple positive-or-negative result, and your pathology report’s specific wording matters.

TNBC vs. Other Breast Cancer Types

Treatment for each subtype is genuinely individualized — this table shows why the biomarker profile, not just “breast cancer” as a general category, shapes the entire treatment conversation.

Is TNBC One Disease?

No — TNBC is a single diagnostic label covering a biologically diverse group of cancers. Research has identified several molecular subtypes within TNBC based on gene-expression patterns, immune characteristics, and other biological features, but it’s important to distinguish research classification from routine clinical practice.

Areas of biological diversity within TNBC include:

• Gene-expression-based subtypes (an active area of ongoing research)
• Immune-related characteristics, which can influence response to immunotherapy
• BRCA/homologous recombination deficiency (HRD) biology, relevant to PARP inhibitor eligibility
• Androgen receptor expression in a subset of tumors
• Other molecular pathways under active investigation

Important distinction: these research-based molecular subtypes are genuinely useful for understanding TNBC’s biology and guiding future treatment development, but they are not yet universally used as routine clinical categories the way stage or grade are. In current practice, treatment decisions rely primarily on stage, specific biomarkers with established clinical utility (like PD-L1 and BRCA status), and response to treatment — not yet on a fully individualized molecular subtype classification, though this is an active and evolving area of research.

Symptoms

TNBC symptoms are generally the same as symptoms of breast cancer overall — there’s no symptom pattern specific to TNBC that distinguishes it from other breast cancer subtypes. TNBC cannot be identified by symptoms alone.

Possible symptoms include:

• A new breast lump
• Thickening in the breast
• A change in breast size or shape
• Skin dimpling
• Nipple inversion
• Nipple discharge, particularly if bloody
• Persistent breast pain, in some cases
• Swelling
• Enlarged lymph nodes in the armpit

A related but distinct presentation worth understanding: rapidly progressive breast swelling, redness, warmth, skin thickening, or an orange-peel appearance of the skin can indicate inflammatory breast cancer — a clinical presentation/subtype defined by how it presents, not by receptor status. Inflammatory breast cancer can have various receptor profiles, including TNBC, but inflammatory breast cancer and TNBC are not the same thing — one describes how the cancer presents, the other describes its biomarker profile, and a cancer could be either, both, or neither.

None of these symptoms — including pain — indicate TNBC specifically; any new or persistent breast change warrants evaluation, but symptoms alone cannot tell you or your doctor which breast cancer subtype, if any, is present.

Causes and Risk Factors

There is no single cause of TNBC. Known risk factors include younger age at diagnosis, inherited BRCA1 mutations, certain family cancer history patterns, and some reproductive and lifestyle factors — though many people diagnosed with TNBC have none of these identifiable risk factors.

It’s worth saying directly: a TNBC diagnosis is not something a person caused through lifestyle choices. Most of the risk factors above are not modifiable, and even the modifiable ones (like weight or activity level) represent one contributing factor among a complex, incompletely understood set of causes — not a reason for self-blame.

BRCA1, BRCA2, and Genetic Testing

TNBC has a meaningfully stronger association with inherited BRCA1 mutations than many other breast cancer subtypes — but most people with TNBC do not have a BRCA mutation. Genetic testing is generally recommended based on age at diagnosis, family history, and current guideline criteria, and results can influence both treatment options and family risk assessment.

Key points:

• A pathogenic BRCA1 mutation is found in a meaningful subset of TNBC patients, particularly those diagnosed at a younger age
• Not every TNBC patient has a BRCA mutation — the majority do not
• Germline genetic testing (testing inherited DNA, typically from blood or saliva) may be recommended based on age, family history, ancestry, and current guideline criteria
• Results can influence treatment decisions (particularly PARP inhibitor eligibility, discussed below) and inform genetic risk counseling for family members

Types of genetic testing:

• Germline testing — looks at inherited DNA, relevant to hereditary cancer risk and family counseling
• Tumor/somatic testing — looks specifically at the tumor’s DNA, which can identify mutations present only in the cancer itself, not necessarily inherited

Genes beyond BRCA1/BRCA2 sometimes tested in appropriate clinical contexts include PALB2, TP53, and other hereditary breast cancer-associated genes, depending on personal and family history.

Genetic counseling — a conversation with a specialist trained in interpreting hereditary cancer risk — is generally recommended alongside genetic testing, both to help decide whether testing is appropriate and to help interpret results once available.

How TNBC Is Diagnosed

Diagnosis follows the general breast cancer diagnostic pathway — starting with clinical examination and imaging, then tissue biopsy to confirm cancer and determine receptor status, including the ER/PR/HER2 testing that defines TNBC specifically.

General diagnostic pathway:

1. Clinical breast examination
2. Diagnostic mammography
3. Breast ultrasound
4. MRI, in selected cases
5. Core needle biopsy
6. Histopathology
7. ER and PR testing
8. HER2 testing
9. Additional biomarker testing, where relevant
10. Staging, where indicated
11. Multidisciplinary treatment planning

Imaging roles:

• Mammography — useful for detecting suspicious breast abnormalities
• Ultrasound — particularly useful for characterizing masses and evaluating lymph nodes in the armpit
• Breast MRI — used in selected patients, particularly when disease extent is unclear, breasts are dense (which can limit mammography), multiple lesions are suspected, or additional information is needed for neoadjuvant treatment planning. MRI is not required for every TNBC patient.

Biopsy: a tissue biopsy is required to confirm breast cancer and determine its receptor status — this generally means a core needle biopsy, often image-guided, and sometimes a lymph node biopsy if nodes appear suspicious.

Biomarker Testing: HER2, PD-L1, and Beyond

HER2 Testing

HER2 status is evaluated by immunohistochemistry (IHC), and in certain cases, in-situ hybridization (ISH) testing is used to clarify results when the IHC result is ambiguous. This distinction matters increasingly because of a nuance worth understanding clearly:

HER2-low and HER2-ultralow are not the same as HER2-positive disease. These terms describe tumors that show some low level of HER2 expression on testing, without meeting the threshold for classic “HER2-positive” breast cancer. This distinction has become clinically relevant in the metastatic setting because certain antibody-drug conjugates (discussed below) can be effective even at these lower HER2 expression levels — but a tumor with HER2-low or HER2-ultralow expression, alongside negative ER and PR, is still generally classified and treated within the TNBC framework for most purposes, with the HER2-low/ultralow status becoming specifically relevant mainly when certain antibody-drug conjugates are being considered.

PD-L1 Testing

PD-L1 testing helps determine eligibility for immunotherapy in certain TNBC treatment settings — but the specific assay, scoring system, and required threshold differ by treatment setting, which is a genuinely important nuance:

• In early-stage, high-risk TNBC, current pembrolizumab approval (based on the KEYNOTE-522 trial) is not dependent on PD-L1 status — it’s used based on stage and risk criteria, regardless of PD-L1 result.
• In metastatic TNBC, current pembrolizumab approval (based on KEYNOTE-355) specifically requires a PD-L1 Combined Positive Score (CPS) of 10 or higher, as determined by an FDA-authorized test.

This is one of the more commonly confused points in TNBC treatment information online — the same drug, pembrolizumab, has different PD-L1 testing requirements depending on whether the disease is early-stage or metastatic, and getting this backwards leads to real confusion about who’s actually eligible for what.

Staging

Breast cancer staging uses the TNM system (Tumor size, Node involvement, Metastasis), but modern breast cancer staging also incorporates tumor biology — including receptor status and grade — into what’s called “prognostic stage,” which can differ from the purely anatomical stage based on size and spread alone.

Anatomical stage vs. prognostic stage: anatomical stage is based purely on tumor size, node involvement, and metastasis. Prognostic stage incorporates additional biological factors like grade and receptor status, and can result in a different overall stage number than anatomical stage alone would suggest. This is a genuinely useful nuance to understand if you notice your stage described slightly differently across different reports or conversations.

It’s worth being clear: not every patient within a given stage receives identical treatment individual factors (tumor biology, biomarkers, overall health, patient preference) shape the specific plan within each stage category.

Treatment Overview

TNBC treatment depends on stage, tumor size, lymph node status, germline BRCA status, PD-L1 status, response to any neoadjuvant therapy, and overall health — there is no single treatment plan that applies to every patient.

Because TNBC lacks the targets that hormone therapy and HER2-targeted drugs work against, chemotherapy has historically been, and often remains, a central part of treatment for both early-stage and metastatic disease. In recent years, this has been substantially supplemented — not replaced — by:

• Immunotherapy, in appropriate biomarker-eligible settings
• PARP inhibitors, for eligible BRCA-mutated patients
• Antibody-drug conjugates, particularly in the metastatic setting
• Radiation therapy, where indicated
• Surgery, as a core part of curative-intent treatment for localized and locally advanced disease
• Clinical trials, given how actively this treatment landscape continues to evolve

Early-Stage TNBC Treatment

For early-stage TNBC, chemotherapy is often an important part of treatment precisely because endocrine and HER2-targeted therapies — the backbone of treatment for other breast cancer subtypes — aren’t effective against truly triple-negative disease.

General approach for higher-risk early-stage disease (this is not the plan for every Stage I patient, many of whom have smaller, lower-risk tumors managed with surgery alone or surgery plus adjuvant chemotherapy):

1. Neoadjuvant (pre-surgery) chemotherapy, often combined with pembrolizumab in eligible high-risk cases
2. Surgery
3. Adjuvant (post-surgery) treatment, based on response to neoadjuvant therapy and specific biomarkers
4. Radiation, when indicated

Not every TNBC patient needs chemotherapy — some smaller, node-negative, lower-risk tumors may be managed with surgery and closer surveillance, though chemotherapy is genuinely central to treatment for a large proportion of TNBC patients given the biology involved. This is an individualized decision based on tumor size, grade, and other risk factors.

Neoadjuvant Therapy and Pembrolizumab

Neoadjuvant treatment means systemic therapy given before surgery. For high-risk early-stage TNBC, the current standard combines chemotherapy with pembrolizumab before surgery, continuing pembrolizumab alone afterward — an approach established by the KEYNOTE-522 trial and approved by the FDA in July 2021.

Potential advantages of neoadjuvant treatment:

• Shrinking the tumor before surgery
• Treating microscopic disease that may already exist elsewhere in the body
• Allowing assessment of how the tumor actually responds to treatment
• Potentially allowing breast-conserving surgery instead of mastectomy in some cases
• Identifying residual disease that can inform additional treatment after surgery

On pembrolizumab in this setting specifically: based on KEYNOTE-522, pembrolizumab combined with chemotherapy before surgery, followed by pembrolizumab alone after surgery, is used for high-risk, early-stage TNBC (generally larger or node-positive tumors meeting specific size/nodal criteria) — importantly, this use is not dependent on PD-L1 status, unlike its use in metastatic disease. This approach showed improved pathologic complete response rates and improved event-free survival, with updated data also showing an overall survival benefit.

This is genuinely powerful, but it’s not without real trade-offs worth understanding honestly: adding pembrolizumab increases the risk of immune-related side effects, which can range from mild to serious and, in rare cases, life-threatening. This is exactly the kind of individualized risk-benefit conversation to have directly with your oncology team rather than assuming pembrolizumab is automatically the right choice for every eligible patient.

Pathologic Complete Response and Residual Disease

Pathologic complete response (pCR) means no invasive cancer is found in the breast or sampled lymph nodes after neoadjuvant treatment, based on the specific pathologic definition used at your center. pCR is associated with better long-term outcomes in TNBC — but it’s important to be precise about what this does and doesn’t mean:

• pCR does not guarantee the cancer can never return
• Patients who don’t achieve pCR (meaning some residual disease is found at surgery) can still achieve long-term disease control — pCR is a strong prognostic indicator, not a binary “cured vs. not cured” outcome

If residual disease is found after neoadjuvant treatment, subsequent treatment decisions may depend on:

• Whether pembrolizumab was already part of neoadjuvant treatment (continuing it into the adjuvant phase where appropriate)
• Germline BRCA status
• Extent of residual disease
• Stage

Potential options in this situation may include continued pembrolizumab where already indicated, capecitabine chemotherapy in selected patients, or olaparib for eligible patients with a germline BRCA mutation and high-risk residual disease — the specific approach genuinely depends on your particular combination of these factors.

Surgery and Radiation

Surgery options:

• Breast-conserving surgery may be possible, particularly after neoadjuvant treatment has shrunk the tumor, if the remaining disease can be adequately removed with acceptable cosmetic and oncologic outcomes
• Mastectomy may be recommended based on tumor extent, multifocal disease, breast size relative to tumor size, genetic factors (like BRCA status, which can affect future cancer risk in the same or opposite breast), response to neoadjuvant therapy, and patient preference
• Lymph node surgery — including sentinel lymph node biopsy, and axillary lymph node dissection in selected patients with more extensive nodal involvement

Radiation therapy may be recommended after breast-conserving surgery, after mastectomy in selected higher-risk patients, when there’s significant lymph node involvement, or for locally advanced disease. Modern techniques (3D conformal radiation, IMRT, image-guided radiation) aim to treat the relevant tissue effectively while limiting exposure to surrounding structures.

Metastatic TNBC

Stage IV or metastatic TNBC means the cancer has spread to distant organs — commonly bone, liver, lungs, or brain. Treatment is systemic (affecting the whole body) and aims to control the cancer, manage symptoms, maintain quality of life, and extend survival. Metastatic TNBC is not automatically untreatable — the treatment landscape here has genuinely expanded in recent years.

Treatment selection for metastatic TNBC depends on PD-L1 status, germline BRCA status, HER2 expression level (including HER2-low status), prior treatment received, disease burden, which organs are involved, symptoms, and overall health — genuinely individualized rather than following one fixed sequence.

Immunotherapy in Metastatic Disease

Pembrolizumab combined with chemotherapy is approved for first-line treatment of metastatic TNBC specifically in patients whose tumors show PD-L1 CPS ≥10 — this is a meaningfully different eligibility threshold than pembrolizumab’s use in early-stage disease.

Based on the KEYNOTE-355 trial, pembrolizumab plus chemotherapy is a standard first-line option for PD-L1 CPS≥10-positive metastatic TNBC, showing improved progression-free and overall survival compared to chemotherapy alone in this specific biomarker-selected group. Not every metastatic TNBC patient is eligible — a PD-L1 CPS below 10 does not meet the criterion for this specific approval, which is exactly why PD-L1 testing is such a pivotal step in metastatic TNBC treatment planning.

For patients who are not candidates for immunotherapy (including those with a PD-L1 CPS below 10, or those with contraindications to immunotherapy), alternative first-line options — including newer antibody-drug conjugate approaches — are discussed in the next section.

PARP Inhibitors

PARP inhibitors may be appropriate for patients with a germline BRCA1 or BRCA2 mutation and HER2-negative breast cancer — this includes many, though not all, TNBC patients, since not every TNBC patient carries a BRCA mutation.

• Olaparib — based on the OlympiA trial, olaparib carries an approved role as adjuvant treatment (after surgery and any chemotherapy) for patients with germline BRCA1 or BRCA2 mutations and high-risk, HER2-negative early breast cancer, showing improved invasive disease-free survival — this was the first PARP inhibitor approval in this specific setting.
• Talazoparib — has an established role in appropriate settings for BRCA-mutated, HER2-negative advanced breast cancer, according to current indications.

Eligibility genuinely depends on the specific clinical setting and current approvals — not every patient with a BRCA mutation automatically receives a PARP inhibitor; this depends on stage, prior treatment, and the specific approved indication that applies to their situation.

Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs) combine an antibody that targets a protein on cancer cells with a chemotherapy payload delivered specifically to those cells. Several distinct ADCs now play a role in metastatic TNBC, each with different, specific eligibility criteria — they are not interchangeable with one another.

This is a genuinely fast-evolving area — the fact that datopotamab deruxtecan’s TNBC-specific approval is quite recent (2026) is a good example of why treatment sequencing in metastatic TNBC should always be confirmed against current guidelines and your oncology team’s up-to-date knowledge, rather than assumed from general information that may become outdated within a year or two.

HER2-Low and HER2-Ultralow Disease

To restate this clearly given how often it’s misunderstood: traditional TNBC classification requires HER2-negative status — but within “HER2-negative,” some tumors show low or ultralow levels of HER2 expression on testing, distinct from having no HER2 expression at all.

• This distinction matters practically because certain antibody-drug conjugates (like trastuzumab deruxtecan) can be effective even at these lower HER2 expression levels in the metastatic setting
• HER2-low/ultralow is not the same as HER2-positive breast cancer — it does not make a tumor eligible for the HER2-targeted therapies used for classic HER2-positive disease
• A tumor can be ER-negative, PR-negative, and HER2-low (or ultralow) and still be managed within the TNBC treatment framework for most purposes, with the HER2-low/ultralow status becoming specifically relevant when certain ADCs are being considered as treatment options

Recurrent TNBC

Recurrence can be:

• Local — in or near the breast/chest wall
• Regional — in nearby lymph nodes
• Distant — at a site away from the original disease (which is, by definition, metastatic recurrence)

Treatment for recurrence depends on time elapsed since initial treatment, prior chemotherapy and immunotherapy received, BRCA and PD-L1 status, HER2 expression level, location of recurrence, prior radiation, and overall health. There is no one universal approach to recurrence — it’s reassessed based on the specific nature of the recurrence and what treatment has already been tried, using the same treatment categories (chemotherapy, immunotherapy, PARP inhibitors, ADCs) discussed throughout this guide, sequenced based on individual circumstances.

Prognosis and Survival

This section requires particular care: there is no single TNBC survival figure that applies to every patient.

Prognosis depends on:

• Stage at diagnosis
• Tumor size
• Lymph node involvement
• Tumor grade
• Response to neoadjuvant therapy (pCR vs. residual disease)
• BRCA status
• PD-L1 status
• Site(s) of any metastatic disease
• Time to recurrence, if applicable
• Overall health

On survival statistics specifically: if you encounter published TNBC survival statistics, check whether they describe localized, regional, or metastatic disease specifically (mixing these produces a meaningless combined figure), and check what treatment era the data reflects — statistics from before modern immunotherapy and antibody-drug conjugate treatment became available may not accurately reflect outcomes achievable with current treatment. Population statistics describe groups, not individuals — no article can tell you “your survival is X%.” That conversation belongs with your oncology team.

On recurrence risk specifically: TNBC has a somewhat distinctive recurrence pattern compared to hormone receptor-positive breast cancer — risk of recurrence tends to be relatively higher in the first several years after diagnosis, generally declining over time for patients who remain disease-free. This is a general pattern, not a rigid timeline that applies identically to every individual.

Follow-Up After Treatment

Follow-up after TNBC treatment typically includes:

• Regular clinical breast examination
• Mammography of any remaining breast tissue, where appropriate
• Monitoring for new symptoms
• Management of any ongoing treatment side effects
• Assessment of any symptoms suggesting recurrence

Routine PET/CT, CT scanning, or tumor-marker blood testing in asymptomatic patients without specific findings prompting further evaluation is generally not presented as a universal requirement in current guidelines for most survivors — imaging and additional testing are typically driven by specific symptoms or findings, not scheduled as routine surveillance for everyone. Your specific follow-up plan should be set by your oncology team based on your stage and individual risk factors.

Prevention and Risk Reduction

• Genetic counseling, where family history or other factors suggest a hereditary component worth investigating
• Maintaining a healthy weight and regular physical activity, which are associated with reduced breast cancer risk broadly
• Limiting alcohol intake
• Smoking cessation
• Appropriate breast cancer screening, following current guidelines for your individual risk level
• Risk-reducing strategies for confirmed high-risk mutation carriers (such as BRCA1 carriers), discussed individually with a genetics specialist, which can include enhanced surveillance or, in some cases, risk-reducing surgery

It’s honest to say plainly: these measures reduce risk meaningfully but don’t eliminate it entirely, and TNBC specifically has a strong hereditary and biological component that isn’t fully addressed by lifestyle factors alone.

TNBC Treatment Cost in India

There is no single price for TNBC treatment in India — cost depends heavily on stage, whether immunotherapy or PARP inhibitors or antibody-drug conjugates are part of your plan, and the specific combination of surgery and radiation required.

Why we’re not quoting a single figure: a patient with small, node-negative Stage I TNBC managed with surgery and standard chemotherapy faces a fundamentally different total cost than a patient with high-risk Stage III disease receiving neoadjuvant chemotherapy plus pembrolizumab, or a patient with metastatic disease on an ongoing antibody-drug conjugate — presenting one “TNBC treatment cost in India” figure would genuinely mislead most individual readers. A personalized estimate, based on your specific pathology, stage, and biomarker results, is the only meaningfully useful number, and that requires review of your actual reports.

Considering India for Treatment

India offers relevant infrastructure for TNBC care at accredited breast cancer centers, including breast surgical oncology (with reconstruction options where appropriate), medical oncology with access to modern systemic therapies, radiation oncology, breast imaging and pathology, genetic testing and counseling, and multidisciplinary tumor board coordination.

This is not a claim that India is automatically “the best” option — the right choice depends on your specific stage, which biomarker-driven therapies your case may benefit from, and practical considerations around travel and follow-up. Worth specifically comparing wherever you’re considering treatment:

• Whether the specific therapies your case may need (particularly newer antibody-drug conjugates or pembrolizumab-based regimens) are actually available and regulatorily approved in that country
• Genetic testing and counseling capability, and turnaround time
• PD-L1 testing availability and turnaround, given how central this is to metastatic treatment eligibility
• Multidisciplinary coordination between breast surgery, medical oncology, and radiation oncology
• Breast reconstruction options and expertise, if relevant to your surgical plan

International Patient Treatment Journey

1. Share biopsy and imaging reports for initial review
2. Confirmation of ER/PR/HER2 status and TNBC diagnosis
3. Review of pathology in full detail
4. Staging determination
5. Assessment of genetic testing needs, including BRCA testing where appropriate
6. Assessment of PD-L1 and other relevant biomarkers
7. Multidisciplinary treatment plan development
8. Treatment and cost estimate, based on your specific plan
9. Medical visa assistance
10. Travel and accommodation planning
11. Treatment initiation — systemic therapy, surgery, and/or radiation as planned
12. Monitoring of response
13. Surgery, where indicated, following any neoadjuvant treatment
14. Radiation/adjuvant treatment, where indicated
15. Ongoing follow-up
16. Return-home care coordination

This process cannot guarantee cure, pathologic complete response, exact treatment duration, exact cost, treatment response, survival, visa approval, or specific hospital outcomes — no legitimate source can guarantee any of these.

Questions to Ask Your Breast Cancer Team

• Is my cancer definitely confirmed as triple-negative?
• What are my specific ER, PR, and HER2 results?
• What is my anatomical stage, and does my prognostic stage differ?
• Is my cancer a candidate for neoadjuvant treatment?
• Should I receive pembrolizumab, and if so, is that based on stage/risk criteria or PD-L1 status?
• Do I need genetic testing, including BRCA1/BRCA2?
• Should I have PD-L1 testing, and what would my CPS result mean for my options?
• Is a breast MRI needed in my specific case?
• Will I need surgery after systemic treatment, and could breast-conserving surgery be an option?
• Will I need radiation?
• What happens if cancer remains after neoadjuvant treatment (i.e., if I don’t achieve pCR)?
• Is olaparib appropriate for me based on my genetic testing results?
• If my disease is metastatic, what does my HER2 expression level (including HER2-low status) mean for my treatment options?
• What happens if my cancer returns or progresses?
• Are clinical trials available that might be relevant to my case?

Frequently Asked Questions

People Ask Further Questions

Where This Leaves You

Hearing “triple-negative” as part of a breast cancer diagnosis can feel like being told your cancer doesn’t have a treatment target — but that’s genuinely not accurate anymore. The treatment landscape for TNBC has expanded meaningfully in recent years: immunotherapy for appropriately selected patients at both the early and metastatic stages, PARP inhibitors for eligible BRCA-mutated patients, and increasingly precise antibody-drug conjugates for metastatic disease, each with their own specific eligibility criteria worth understanding clearly rather than assuming interchangeably.

If you’re evaluating treatment options, including treatment in India, the most useful first step is sharing your complete pathology report — including ER/PR/HER2 results, any genetic testing, and PD-L1 status if already tested — for an individualized review. Shifam Health can help coordinate that record review, hospital and specialist selection, treatment cost estimates, and medical visa guidance, while the actual diagnosis, staging, and treatment decisions remain with your breast oncology team.